Table 2 Baseline and annual clinical, laboratory, and MRI characteristics according to MRI evidence of erosion progression at 1 year in patients with RA in remission
Characteristics | Baseline | P | 1 Year | P | ||
|---|---|---|---|---|---|---|
Progression (n = 25) | No progression (n = 51) | Progression (n = 25) | No progression, (n = 51) | |||
Clinical variables | ||||||
TJC28 | 6.3 ± 5.8 | 4.2 ± 3.6 | 0.06 | 0 | 0 | – |
SJC28 | 3.6 ± 2.1 | 2.9 ± 1.8 | 0.14 | 0 | 0 | – |
DAS28 | 4.5 ± 2.5 | 3.6 ± 2.1 | 0.11 | 1.9 ± 0.8 | 1.6 ± 0.7 | 0.10 |
ESR | 38.3 ± 18.9 | 29.8 ± 17.6 | 0.06 | 12.1 ± 8.2 | 14.5 ± 9.4 | 0.29 |
CRP | 21.6 ± 10.2 | 15.6 ± 8.8 | 0.01 | 7.3 ± 4.6 | 6.5 ± 5.2 | 0.52 |
RF | 19/25 (76%) | 40/51 (78.4%) | 0.22 | 16/25 (64%) | 37/51 (72.5%) | 0.15 |
CCP | 21/25 (84.0%) | 42/51 (82.3%) | 0.25 | 20/25 (80%) | 39/51 (76.5%) | 0.23 |
MRI | ||||||
Synovitis | 6.3 ± 3.4 | 5.9 ± 2.9 | 0.60 | 4.6 ± 2.0 | 3.7 ± 2.6 | 0.13 |
Tenosynovitis | 5.2 ± 3.8 | 4.6 ± 3.6 | 0.51 | 2.1 ± 0.9 | 1.7 ± 0.8 | 0.06 |
BME | 8.3 ± 6.4 | 3.7 ± 3.1 | < 0.001 | 4.8 ± 3.6 | 3.1 ± 2.1 | 0.01 |
Bone erosion | 9.9 ± 8.6 | 8.1 ± 6.9 | 0.34 | 13.5 ± 9.6 | 4.4 ± 3.6 | < 0.001 |